Core Viewpoint - Yunnan Betaini Biotechnology Group Co., Ltd. plans to use part of its raised funds to temporarily supplement working capital, addressing a temporary cash flow gap due to market changes [1][2]. Fundraising and Usage - The company raised a total of 3,636 million shares at a price of 47.33 yuan per share, totaling 3,010 million yuan, with a net amount of 2,884 million yuan after deducting issuance costs [1]. - The total investment for projects funded by the raised capital is 1,535 million yuan, with excess funds amounting to 1,349 million yuan [1]. - Previous arrangements for the use of excess funds include: - 2021: 400 million yuan for permanent working capital [2]. - 2023: Up to 320 million yuan for temporary working capital, fully repaid by August 8, 2024 [2]. - 2024: 360 million yuan for the "Betaini Central Factory Phase II Project" [2]. - 2024: Up to 320 million yuan for temporary working capital, fully repaid by August 14, 2025 [2]. - 2025: Up to 700 million yuan of idle raised funds and 2,500 million yuan of idle self-owned funds for cash management [2]. - As of August 14, 2025, the balance of excess funds was 325 million yuan, with 340 million yuan allocated for cash management [2]. Board Approval and Compliance - The proposal to use up to 320 million yuan of excess funds for temporary working capital has been reviewed and approved by the audit committee and independent directors, confirming compliance with relevant regulations [3]. - The sponsoring institution, Guosen Securities Co., Ltd., has no objections to this matter [3].